PreveCeutical Medical (PRVCF, PREV) is an early stage life sciences company with a focus on curative and therapeutic compounds based on natural substances. Recent announcements point to value creation by PreveCeutical in recent months. The research and development team has made significant progress with several projects. The updates appear to confirm the Company has been successful in deploying capital raised earlier in 2018 to push forward its pipeline of therapies based on natural compounds. Management also appears to make current revenue a priority, pursuing acquisitions and supply agreements that could raise cash flows in the near-term.
Unfortunately, the progress and resulting fundamental value has not been recognized by investors. After a strong upward surge in early October 2018 in response to an announcement of R&D pipeline progress, the stock has traded downward and trading volume has slipped. We believe the price action and trading volume decline are due in part to a shift in risk appetite in the broader U.S. and Canadian equity markets. We expect this to be a temporary condition until concerns about macroeconomic conditions are addressed.
Click on the image below to read additional details are available our more recent ten-page report.
Please note disclaimers and disclosures are the end of all Crystal Equity Research reports.